COLORADO SPRINGS, Colo., Nov. 4, 2015 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be participating in two upcoming investor conferences.
Spectranetics management is scheduled to present at the 2015 Stifel Healthcare Conference in New York City on Wednesday, November 18, 2015 at 11:45am ET.
Spectranetics management is also scheduled to present at the 2015 Canaccord Genuity Medical Technology and Diagnostics Forum in New York City on Thursday, November 19, 2015 at 11:00am ET.
Interested parties can access the live audio webcast for each event at http://www.spectranetics.com. An archived presentation of each webcast will be available on the website for 30 days.
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt® scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.